BG
BIIB icon

Bahl & Gaynor’s Biogen BIIB Stock Holding History

Bahl & Gaynor’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-652
Closed -$206K – 329
2020
Q1 		$206K Buy
+652
New +$198K ﹤0.01% 320
2019
Q1 		– Sell
-893
Closed -$269K – 347
2018
Q4 		$269K Sell
893
-32
-3% -$10.2K ﹤0.01% 318
2018
Q3 		$327K Sell
925
-71
-7% -$24.4K ﹤0.01% 332
2018
Q2 		$289K Buy
996
+53
+6% +$14.9K ﹤0.01% 341
2018
Q1 		$258K Buy
943
+18
+2% +$5.59K ﹤0.01% 374
2017
Q4 		$295K Sell
925
-32
-3% -$10.3K ﹤0.01% 372
2017
Q3 		$300K Sell
957
-171
-15% -$50.6K ﹤0.01% 363
2017
Q2 		$306K Buy
+1,128
New +$298K ﹤0.01% 374
2016
Q4 		– Sell
-645
Closed -$202K – 387
2016
Q3 		$202K Buy
+645
New +$191K ﹤0.01% 382
2016
Q1 		– Sell
-692
Closed -$212K – 409
2015
Q4 		$212K Buy
+692
New +$199K ﹤0.01% 411
2015
Q3 		– Sell
-642
Closed -$259K – 434
2015
Q2 		$259K Sell
642
-77
-11% -$30.9K ﹤0.01% 406
2015
Q1 		$304K Buy
+719
New +$283K ﹤0.01% 376

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bahl & Gaynor's BIIB Position: Q2 2020 in Review

Bahl & Gaynor sold out of Biogen (BIIB) in Q2 2020, closing a stake of 652 shares — an estimated $206K sold.

Bahl & Gaynor first reported a position in BIIB in Q1 2015 and held it in 12 quarters. The position peaked at $327K in Q3 2018. 1,060 funds tracked by Wall St. Rank hold BIIB as of Q2 2020.

  • Bahl & Gaynor reported no remaining Biogen position as of Q2 2020 after selling out during the quarter.
  • Bahl & Gaynor sold 652 Biogen shares in Q2 2020, an estimated $206K.
  • Bahl & Gaynor first reported a position in Biogen in Q1 2015 and held it in 12 quarters.
  • Bahl & Gaynor's Biogen position peaked at $327K in Q3 2018.
  • 1,060 funds tracked by Wall St. Rank held Biogen as of Q2 2020.

Based on Bahl & Gaynor's 13F filing for Q2 2020, filed 13 Aug 2020.